li001

AKT Inhibitor Afuresertib Plus Fulvestrant Improves Outcomes in HR-Positive HER2-Negative Breast Cancer with Resistance Mutations

Targeted Therapy /

The phase 3 AFFIRM-205 trial shows that the combination of afuresertib and fulvestrant significantly improves outcomes in patients with advanced HR-positive HER2-negative breast cancer with PIK3CA/AKT1/PTEN pathway alterations. Many of these patients had already developed resistance after prior treatments, including CDK4/6 inhibitors. The study met its main goal, showing that the combination delayed disease progression […]

AKT Inhibitor Afuresertib Plus Fulvestrant Improves Outcomes in HR-Positive HER2-Negative Breast Cancer with Resistance Mutations Read More »

EZH2 Inhibitor Mevrometostat Advances to Phase 3 Trials in Metastatic Castration-Resistant Prostate Cancer

Clinical Trails /

The EZH2 inhibitor mevrometostat is moving into phase 3 trials as a potential treatment for metastatic castration-resistant prostate cancer after encouraging early results. The approach targets EZH2, an epigenetic regulator that helps cancer cells become more aggressive and resistant to treatment, including androgen receptor pathway inhibitors like enzalutamide. In a phase 1 study, combining mevrometostat

EZH2 Inhibitor Mevrometostat Advances to Phase 3 Trials in Metastatic Castration-Resistant Prostate Cancer Read More »

ctDNA and Targeted Combinations Help Overcome Resistance in EGFR-Mutated Non-Small Cell Lung Cancer

Precision Medicine /

Real-world data and circulating tumor DNA (ctDNA) are helping doctors detect and overcome treatment resistance in EGFR-mutated non-small cell lung cancer. Resistance patterns vary by treatment. With osimertinib alone, common causes include MET amplification and secondary EGFR mutations. In combination therapy, such as osimertinib plus chemotherapy, resistance can also involve small cell transformation. Newer combinations

ctDNA and Targeted Combinations Help Overcome Resistance in EGFR-Mutated Non-Small Cell Lung Cancer Read More »

Personalized T-Cell Vaccine Shows Promise in Chronic Lymphocytic Leukemia Patients on BTK Inhibitors

Clinical Trails /

A phase 1 trial suggests that the multipeptide T-cell activator iTAC-XS15-CLL could be a safe and promising immunotherapy for patients with chronic lymphocytic leukemia receiving BTK inhibitors. The study enrolled 20 patients with minimal residual disease who were in partial remission after treatment with ibrutinib, acalabrutinib, or zanubrutinib. Each patient received three doses of a

Personalized T-Cell Vaccine Shows Promise in Chronic Lymphocytic Leukemia Patients on BTK Inhibitors Read More »

PI3K Signaling in Pancreatic Cancer Can Bypass KRAS Through PTEN Oxidation

Research Advances /

A new study is reshaping understanding of pancreatic ductal adenocarcinoma (PDAC), showing that PI3K signaling—key to tumor growth—can persist without direct activation by mutant KRAS. Researchers found that a common mutation, KRAS G12R, cannot activate PI3K, yet tumors still maintain strong pathway activity, suggesting an alternative mechanism is at work. The study points to the

PI3K Signaling in Pancreatic Cancer Can Bypass KRAS Through PTEN Oxidation Read More »

Netrin-1 Pathway Found to Drive Tumor Growth and Nerve Expansion in Pancreatic Cancer

Research Advances /

A new study highlights the Netrin-1 (NTN1) and Neogenin-1 (NEO1) signaling pathway as a major driver of pancreatic ductal adenocarcinoma (PDAC). Researchers found both proteins are highly overexpressed in tumors, fueled by KRAS mutations and stress signals from nearby nerves. These pathways create a self-reinforcing loop that supports tumor growth and spread. The research shows

Netrin-1 Pathway Found to Drive Tumor Growth and Nerve Expansion in Pancreatic Cancer Read More »

KRAS-Targeted Therapies Signal New Direction in Pancreatic Cancer Treatment

Research Advances /

Researchers are shifting how they treat pancreatic ductal adenocarcinoma (PDAC), focusing on the KRAS mutation that drives more than 90% of cases. This mutation locks KRAS in an “on” state, causing continuous cancer cell growth and making the disease resistant to many standard treatments, including immunotherapy. New findings show KRAS also shapes the tumor’s immune

KRAS-Targeted Therapies Signal New Direction in Pancreatic Cancer Treatment Read More »

FDA Review Sought for zenocutuzumab-zbco in NRG1 Fusion–Positive Bile Duct Cancer

Clinical Trails /

Partner Therapeutics has submitted a supplemental application to the U.S. Food and Drug Administration seeking approval of zenocutuzumab-zbco for adults with advanced or metastatic cholangiocarcinoma carrying NRG1 gene fusions. The National Comprehensive Cancer Network has already added the drug to its guidelines as a recommended option in biliary tract cancers. The submission is supported by

FDA Review Sought for zenocutuzumab-zbco in NRG1 Fusion–Positive Bile Duct Cancer Read More »

Oral Darovasertib–Crizotinib Combo Shows Strong Results in Hard-to-Treat Eye Cancer

Rare Cancers /

The OptimUM-02 trial shows that the oral combination of darovasertib and crizotinib significantly improves outcomes for patients with a difficult-to-treat form of eye cancer, metastatic uveal melanoma that is HLA-A*02:01–negative. The treatment doubled median progression-free survival to 6.9 months compared to 3.1 months with standard therapies. It also reduced the risk of disease progression or

Oral Darovasertib–Crizotinib Combo Shows Strong Results in Hard-to-Treat Eye Cancer Read More »

Mevrometostat Combo Therapy Shows Strong Early Results in Advanced Prostate Cancer

Treatment /

Mevrometostat, an experimental EZH2 inhibitor, is showing strong potential for treating metastatic castration-resistant prostate cancer by blocking “lineage plasticity,” a process that allows cancer cells to change and resist hormone therapy. When combined with enzalutamide, the treatment significantly improved outcomes in early studies. In a phase 1 trial, the combination nearly doubled median radiographic progression-free

Mevrometostat Combo Therapy Shows Strong Early Results in Advanced Prostate Cancer Read More »